Antitrust Antitrust

Drugmakers told to manage antitrust risk in China, following a flurry of high-profile fines

By MLex Staff
  • 16 Jun 2023 07:47
  • 16 Jun 2023 07:47
Drugmakers, including those that produce raw ingredients, have been ordered by China's antitrust regulator to thoroughly scrutinize their business practices, after the authority slapped a series of fines on industry players in recent months.
Representatives of the China Pharmaceutical Industry Association, the China Society for Drug Regulation and several manufacturers

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

Latest News